Artikel ; Online: Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China.
2023 Band 26, Heft 1, Seite(n) 1424–1431
Abstract: Aim: To assess the economic burden of different chemotherapies for lung cancer patients and influencing factors in China.: Materials and methods: The economic burden of lung cancer, including direct, indirect and intangible costs was measured within ... ...
Abstract | Aim: To assess the economic burden of different chemotherapies for lung cancer patients and influencing factors in China. Materials and methods: The economic burden of lung cancer, including direct, indirect and intangible costs was measured within three months after diagnosis and treatment. Direct cost included the cost of hospitalization, outpatient visits, out-of-pocket drug purchases, costs of transportation, accommodation and meal expenses while seeking treatments in hospitals. Cost information was attained from questionnaire and patients' medical record. Indirect cost was measured by the patients' and their caregivers' productive days lost due to outpatient visits and hospitalization for lung cancer treatment. Intangible cost was obtained through the willingness-to-pay method from a questionnaire completed by the patient. Results: Among the total cost of CNY71,401.92, direct cost, indirect cost and intangible cost constituted 89.02%, 4.29%, and 6.69% respectively. Educational level, occupation, family income, lung cancer classification, and the city of residence significantly influenced the total cost. Limitations: Limitations in our study included: First, our follow-up period of three months was relatively short compared to the whole survival period of lung cancer patients. Second, the sample size of the chemotherapy combined with targeted therapy group was not large enough, and the cost data obtained would need confirmation in future studies. Third, participants came from only two localities, which may somewhat limit the representativeness of the study results for the whole of China. Conclusions: The economic burden of lung cancer treatment mainly came from the cost of the drugs. Patients taking chemotherapy had significantly higher cost compared to patients using targeted therapy. The cost was generally higher for those with higher educational level, those with higher family income, and those living in an economically more developed city. Patients with NSCLC had higher cost compared to patients with SCLC. |
---|---|
Mesh-Begriff(e) | Humans ; Lung Neoplasms/drug therapy ; Gefitinib/therapeutic use ; Financial Stress ; Carcinoma, Non-Small-Cell Lung/drug therapy ; China |
Chemische Substanzen | Gefitinib (S65743JHBS) |
Sprache | Englisch |
Erscheinungsdatum | 2023-10-31 |
Erscheinungsland | England |
Dokumenttyp | Journal Article |
ZDB-ID | 2270945-9 |
ISSN | 1941-837X ; 1369-6998 |
ISSN (online) | 1941-837X |
ISSN | 1369-6998 |
DOI | 10.1080/13696998.2023.2272536 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 6450: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.